Biomotion Sciences Ordinary Shares (SLXN) Income Statement Analysis

See more : Grupo Financiero Inbursa, S.A.B. de C.V. (GPFOY) Income Statement Analysis – Financial Results

Complete financial analysis of Biomotion Sciences Ordinary Shares (SLXN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biomotion Sciences Ordinary Shares, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Biomotion Sciences Ordinary Shares (SLXN)

Industry: Biotechnology

Sector: Healthcare

Website: https://silexion.com

About Biomotion Sciences Ordinary Shares

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Unable to fetch income statement for: SLXN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

November 22, 2024globenewswire.com

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives Trading on split-adjusted basis will begin...

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

November 20, 2024globenewswire.com

GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company's management will be attending and presenting at the Noble Capital Markets...

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

October 1, 2024businesswire.com

GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)---- $SLXN #BioTech--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization...

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

September 24, 2024benzinga.com

Silexion Therapeutics Corp. SLXN stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

September 24, 2024businesswire.com

GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)---- $SLXN #BioTech--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced significant new findings from its Phase 2 trial of LODER™ in patients...

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

September 3, 2024globenewswire.com

GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment...

Source: https://incomestatements.info
Category: Stock Reports

Biomotion Sciences Ordinary Shares (SLXN) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories